The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,
but new platinum agents have been very slow to enter the clinic. Recently, however, there …

Anticancer platinum (Pt) complexes have long been considered to be one of the biggest
success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for …

Cisplatin plays a pivotal role in the treatment of various malignant tumors, but its therapeutic
effects are hampered by drug resistance. Pt (IV) prodrugs represent a promising class of …

Platinum compounds represent one of the great success stories of metals in medicine.
Following the serendipitous discovery of the anticancer activity of cisplatin by Rosenberg, a …

Platinum-based anticancer drugs dominate the chemotherapy field for several cancers, but
problems such as systemic toxicity and acquired resistance for some primary tumors hamper …

In this manuscript we focus on Pt (IV) anticancer prodrugs. We explore the main working
hypotheses for the design of effective Pt (IV) prodrugs and note the exceptions to the …

Owing to the unique DNA damaging cytotoxicity, platinum (Pt)-based chemotherapy has
long been the first-line choice for clinical oncology. Unfortunately, Pt drugs are restricted by …

Platinum (II)-based drugs are widely used for the treatment of solid tumors, especially in
combination protocols. Severe side effects and occurrence of resistance are the major …

Platinum-based anticancer drugs have been widely applied in clinical settings for more than
40 years. The remarkable breakthroughs that have come from the use of these complexes in …

Platinum drugs are commonly used in cancer therapy, but their therapeutic outcomes have
been significantly compromised by the drug resistance of cancer cells. To this end, intensive …